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Article 
 
Cryomilled Zinc Sulfide: a prophylactic for Staphylococcus aureus infected 
wounds 
 
Abstract 
Bacterial pathogens that colonize wounds form biofilms which protect the bacteria 
from the effect of host immune response and antibiotics. This study examined the 
effectiveness of newly synthesized zinc sulfide in inhibiting biofilm development by 
Staphylococcus aureus (S. aureus) strains. Zinc sulfide (ZnS) was anaerobically 
biosynthesized to produce CompA which was further processed by cryomilling to 
maximize the antibacterial properties to produce CompB. The effect of the two 
compounds on the S. aureus strain AH133 were compared using zone of inhibition 
(ZOI) assay. The compounds were formulated in a polyethylene glycol (PEG) cream. 
We compared the effect of the two compounds on biofilm development by AH133 
and two Methicillin-resistant S. aureus (MRSA) clinical isolates using the in vitro 
model of wound infection. ZOI assay revealed that CompB is more effective than 
CompA. At 15 mg/application, the formulated cream of either compound inhibited 
biofilm development by AH133 which was confirmed using confocal laser scanning 
microscopy. At 20 mg/application, CompB inhibited biofilm development by the two 
MRSA clinical isolates. To further validate the effectiveness of CompB, mice were 
treated using the murine model of wound infection. CFU assay and in vivo live 
imaging results strongly suggested the inhibition of S. aureus growth.  
Keywords 
ZnS Particles, anti-Biofilm, Staphylococcus aureus, anti-MRSA, Cryomilling 
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Introduction 
Wounds, acute and chronic, constitute a serious challenge to the health care system. 
Severely burned patients are immune-compromised due to the loss of skin barriers 
and the induced modulation of the specific and non-specific immune responses.1 
Colonization of burned tissues by different bacterial pathogens often leads to sepsis 
and a high mortality rate.2 Other chronic wounds include pressure ulcers, venous 
ulcers, diabetic ulcers, and neuropathic ulcers.3,4 Incomplete removal of bacterial 
pathogens from the acute wound prolongs the inflammatory process, delaying the 
wound healing process, and potentially causing the transition of an acute wound into a 
chronic one.5,6 Burn wounds may be rapidly colonized by commensal bacteria, both 
gram positive and gram negative.7 On colonizing a wound, these bacteria become 
pathogenic, accelerating their reproduction rate. 
At different infection sites, including wounds, bacteria may produce a protective 
structure termed a biofilm.8 Biofilms are complex structures that envelop bacteria in a 
self-secreted extracellular polysaccharide matrix (EPS).9 Within the biofilm, bacteria 
are protected from antibiotics and the host immune responses.10,11 The antibiotic 
resistance of the biofilm may reach 100 fold higher than that of the planktonic cells, 
which may contribute significantly to the failure of treatment of infected acute and 
chronic wounds.11-13 Antibiotic resistance among bacterial pathogens is developing at 
an alarming rate. Therefore, it is critical that alternative antimicrobial agents are 
developed that can be produced in bulk with repeatable characteristics.14 
For this purpose, we propose a novel two-step approach for the biosynthesis of 
ZnS. Unlike traditional synthesis methods of ZnS, the proposed method does not 
require organic solvents and its basis on microbial synthesis improves the 
biocompatibility of the particles. The antibacterial abilities of ZnS derived from 
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traditional methods, such as one-pot colloidal synthesis15 and chemical precipitation16, 
have been tested on Escherichia coli, Pseudomonas aeruginosa, Actinomycete, 
Salmonella typhi, Bacillus subtilis and Klebsiella planticola, deriving promising 
results.15-17 The fabrication process we used is a more eco-friendly, reproducible and 
economical method of biosynthesis of ZnS, augmented by cryomilling as a scalable 
post-processing technique. Cryomilling is the mechanical attrition of powders under 
cryogenic conditions,18 which was used to decrease the particle size in this study. 
Smaller sized particles have larger surface to volume ratio, resulting in larger surface 
in direct contact with the exterior environment under the same amount of antibacterial 
agents, thus it is expected that agents with smaller particle size will possess higher 
antibacterial properties.19. For such cryomilled ZnS powder to be used clinically, its 
biocompatibility must be confirmed. Macrophages, present in almost all tissues, are 
normally activated during bacterial infection and inflammatory response, being 
responsible for the digestion of unwanted or foreign materials via phagocytosis.20 
Therefore, it is speculated that cryomilled microbially synthesized ZnS will derive an 
improved antibacterial response when exposed to S. aureus or in biofilm models, 
whilst not eliciting a significant macrophagic reaction. 
Materials and Methods 
Materials 
ZnS preparation.  A two-step fabrication approach was used to generate the ZnS 
particles. First, ZnS particles were extracellularly biosynthesized using the fast-
growing metal-reducing thermophilic bacterium, Thermoanaerobacter, X513.18 
Media used were modified from TOR-39 medium, the ingredients were described by 
previous work.19 The dissolved basal medium was boiled with N2 gas purging and 
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cooled with continuous N2 gas purging. Incubation was initiated with inoculation of 
glucose, thiosulfate as a sulfur source, and 2 vol. % mid-log growth X513 culture. 
After cell growth and development of H2S, aliquots of zinc chloride were (ZnCl2, 
reagent grade > 98%) dosed. The precipitate of ZnS particles was recovered by 
centrifugation and washed more than three times with deionized water and stored as 
freeze-dried solid samples. The original as-biosynthesized ZnS particles were labeled 
as CompA. 
Part of the biosynthesized ZnS particles were then cryomilled using the freezer 
mill 6870 (SPEX, Metuchen, NJ, USA), which was operated under a cryogenic 
environment of -196°C.21 Five grams of biosynthesized ZnS particles were used for 
cryomilling, and the parameters used were: 5 min precool, 8 cycles, 7 min run time 
for each cycle, 2 min cool time in between each two cycles and 15 counts per second 
(CPS) for milling. The total time period for cryomilling was 56 min.19,21 Samples 
acquired using this method were labeled as CompB. 
Scanning Electron Microscopy (SEM) Analysis 
The morphology of ZnS particles was imaged using a JEOL JCM-6000 NeoScope 
Benchtop Scanning Electron Microscope (SEM) (Nikon Instruments, Elgin, IL, 
USA). In order to clearly observe the morphology of the samples, the images were 
taken under 15 kV accelerating voltage, high vacuum, and magnification of 5000X, 
using secondary imaging mode. The images were analyzed using the JCM-6000 
software version 1.1 (Nikon Instruments, Elgin, IL, USA). 
X-ray Diffraction (XRD) Analysis 
The ZnS particles were analyzed using a Rigaku MiniFlex 600 X-ray Diffractometer 
(Rigaku Inc, Woodlands, TX, USA) to determine the particles’ composition and 
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corresponding crystal structures. The voltage and current X-ray generator applied 
were 40 kV and 15 mA, with Cu as the source of X-rays. The XRD profiles were 
analyzed using the PDXL software version 2.1.3.4. 
Bacterial Strain and Media 
The strain of S. aureus utilized in the majority of experiments considering 
antibacterial action was AH133.22 AH133 carries plasmid pCM11 which contains the 
gene that codes for the green fluorescent protein.22 The strain was grown in either LB 
Broth or on LB Agar plates at 37 °C. To maintain the plasmid, erythromycin was 
incorporated in the growth medium at a concentration of 1 µg/ml. We also utilized 
two S. aureus clinical isolates; MRSA 121 and MRSA 139. The isolates were 
obtained from patients at Texas Tech University Medical Center, Lubbock, Texas, 
under a protocol approved by the Institutional Review Board.   
Zone of Inhibition (ZOI) Assay 
The bacteria were grown overnight in LB broth and diluted in a fresh LB broth to an 
optical density (OD600) of 0.5. A 100 μl aliquot containing approximately 108 CFU/ml 
was spread on the surface of the LB agar plate. Samples of the ZnS particles (50 
mg/sample) were placed at three spots on the LB agar surface, with at least 24 mm 
(center to center) between them. The plates were incubated at 37 °C for 24 hours 
before assessment. The diameters of the zones of complete inhibition, including the 
diameter of the disk, were measured to the nearest millimeter with a ruler. 
In vitro Biofilm Model 
The biofilms were developed and assayed as previously described with some 
modifications.8,23 Briefly, tested strains were grown overnight, washed once with 
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PBS, re-suspended in PBS to an OD600 of 0.5 (~10
8 CFU/mL), and serially diluted 
(10- fold). Three sterile cellulose discs with diameter of 6 mm were placed on the 
surface of freshly prepared LB agar with at least 24 mm (center to center) between 
them, and 10 µl containing 102-103 CFU of tested strain was inoculated onto each 
disc. The discs were then treated with either polyethylene glycol (PEG) (control) 
(PEG Ointment Base, B1300, Spectrum, Gardena, CA, USA) or ZnS particles in PEG 
to cover the disc. The plates were then incubated at 37°C for 24 hours. Following 
incubation, the discs were rinsed lightly to remove any unattached bacteria, and the 
biofilms were quantified using the CFU assay. The discs were transferred to a 1.5 ml 
microfuge tube in 1 ml of PBS and sonicated for 10 minutes. The tubes were then 
vortexed for one minute to disrupt and disperse the biofilm. Bacterial suspensions 
were serially diluted 10-fold in PBS, and 10 µl aliquots of each dilution and undiluted 
suspension were plated on LB agar. The plates were air dried and incubated at 37oC 
for 24 hours before the results were read. The number of CFU/disc was determined as 
described above, using the formula CFU/disc = (CFU counted × dilution factor) × 
100. All experiments were done in triplicate. 
Confocal Laser Scanning Microscopy (CLSM) Analysis 
The biofilms were visualized using confocal laser scanning microscopy (CLSM). The 
biofilms were developed as described above. After 24 hours of incubation at 37oC, the 
discs were gently rinsed to remove loosely attached bacteria. Visualization of the S. 
aureus AH133 biofilms was accomplished by using a Nikon A1+/AIR+ Confocal 
Microscope (Nikon Inc., Melville, NY, USA) with images acquired at 2 µm intervals 
through the biofilms. Two and/or three-dimensional images were acquired using the 
Nis Elements Imaging software v. 4.20 (Nikon Inc., Melville, NY, USA). Several 
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image stacks of each biofilm were examined by CLSM, and the images were analyzed 
as previously described.24 Experiments were done in triplicate. 
Confirming the Cytocompatibility of ZnS 
A murine macrophagic cell line (RAW 264.7) was used to test the cytocompatibility 
of CompA and CompB. The cells, at passage 10, were cultivated in standard DMEM 
medium (SigmaAldrich, Irvine, UK) supplemented with 10% FBS (Invitrogen, 
Paisley, UK) and 1% penicillin/streptomycin (100U/ml/100 µg/ml, Invitrogen, 
Paisley, UK). When confluent, cells were trypsinized, counted and subsequently 
seeded into a 96-well plate at the concentration of 3x104 cells/well in a volume of 
100µl of medium. Cells were then incubated for 24 hours at 37 °C, 5% CO2, and 
subsequently exposed to CompA and CompB. Cytotoxicity was tested by treating 
macrophages with powder suspensions in standard medium, as seen elsewhere.25 
CompA and CompB were weighed and resuspended in standard medium at the 
concentration of 0.84% w/v (0.05 g powder in 6 ml of standard medium), creating 
StockA medium and StockB medium, respectively. Each stock medium was then 
transferred into a Pyrex bottle and autoclaved at 121°C for 15 minutes. StockA and 
StockB media were cooled to room temperature, then diluted to a final concentration 
of 3 µl/ml using standard medium (3 µl of Stock medium/1 ml of standard medium). 
The new solutions were named CompA medium and CompB medium and were then 
added to cell culture at 100 µl/well. Cells were incubated with CompA media and 
CompB media for 24 hours at 37 °C, 5% CO2. At the end of the incubation time, 
CompA media and CompB media were replaced with fresh, standard medium and 
cells were incubated for a further 24 hours, before proceeding with the cell viability 
test. 
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In vivo Murine Model of Wound Infection 
A group of three to four mice (including a control group) adult female Swiss Webster 
mice weighing 20-24 g was anesthetized using a mixture of isoflurane and oxygen 
and their backs were shaved.  Shaved areas were completely cleansed with 95% 
ethanol and a superficial wound was created by centrally lifting the skin with surgical 
tweezers and removing 0.7 x 0.7 cm of skin with surgical scissors. Either control PEG 
or CompB/PEG gauze (1 cm2) was placed on the wound.  The gauzes were secured in 
place by applying a clear OPSITE dressing over the back of the mouse. Aliquots 
containing ~103 CFU of bacteria in 20 μl were injected in the area between the gauze 
and the wound. The mice were monitored twice a day for signs of infection or 
distress. After 5 days of observation, the mice were euthanized.  Gauzes were 
removed, and the infected wound bed (this includes all infected connective tissues) 
was excised, weighed, and suspended in 1 ml of PBS.  The extracted gauze and tissue 
were gently rinsed in PBS and homogenized in PBS.  The biofilms were then 
analyzed by CFU assay.  Prior to testing, the tissues were weighed and then 
homogenized in 2 ml of PBS.  Animals were treated in accordance with the protocol 
approved by the Institutional Animal Care and Use Committee at Texas Tech 
University Health Sciences Center in Lubbock, TX. 
Colony-Forming Unit Assays 
Bandage:  The biofilm assay was performed as previously described with some 
modifications.26-28 Bacteria were grown overnight, washed once with PBS (pH 7.4), 
re-suspended in PBS (pH 7.4) to an optical density (OD600) of 0.5 (10
8 CFU/mL), and 
serially diluted [10-fold]. Twenty microliter aliquots containing 103 colony-forming 
units were injected under either an untreated (control) PEG gauze, or test gauze 
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coated with CompB/PEG on the back of a mouse.  These were allowed to grow for 5 
days.  Biofilms were quantified by determining the CFU per square centimeter of 
gauze. After removal from the mouse, each gauze piece was gently washed twice with 
sterile PBS to remove any planktonic bacteria. Excess PBS was drained from the 
gauze by touching it to a sterile filter paper and the gauze was then transferred to a 
sterile homogenized tube containing 2 ml of PBS for enumeration of bacteria.  The 
gauzes were homogenized to loosen the cells within the biofilm and then vigorously 
vortexed 3 times for 1 min to detach the cells.  Suspended cells were serially diluted 
(10-fold) in PBS, and 10-μL aliquots of each dilution were spotted onto LB Agar 
plates. The results were reported as attached CFU per a square centimeter of gauze. 
All experiments were done at least in triplicate. 
Tissue:  At the end of the experiment (5 days), the mouse was euthanatized and 
the tissue of the wound was removed.  The tissues were weighed. This was then 
homogenized and used for a CFU assay in a manner similar to that used for the gauze 
above. The results were reported as attached CFU per gram of tissue. All experiments 
were done at least in triplicate. 
Live Animal Imaging Studies using IVIS 
After 5 days, the biofilms on the wounds of the mice were visualized and imaged 
using IVIS - Live Whole Animal Body Imaging System (Perkin Elmer, 
Massachusetts, USA) as previously described.28 This instrument allows us to have a 
direct detection of pathogens infection in living animals to be monitored by 
bioluminescence.  In this case we used bacterium, S. aureus Lux, that had the Lux 
gene incorporated into its plasmid (S. aureus Lux). Bioluminescence offers a method 
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for monitoring pathogen infections in vivo that is sensitive and noninvasive and 
requires fewer animals than conventional methodologies. 
Cell Viability Assay  
Cell viability was investigated using CellTiter-Blue Cell Viability Assay (Promega, 
Southampton, UK) after 24 and 48 hours from the end of the treatment with CompA 
and CompB media. Briefly, 20µl/well of the reagent were added to cells grown in a 
96-wells plate, according to the manufacturer's protocol. Then, cells were incubated at 
37 °C, 5% in CO2 for 2 hours. At the end of the incubation time, the supernatant of 
each well was transferred in a fresh 96-wells black plate, glass bottom, and 
fluorescence was measured with a microplate reader (Modulus™ II Microplate 
Multimode Reader, Turner Biosystems, Sunnyvale, California, USA) at 560/690 nm. 
Cells grown in standard medium were used as controls and samples were investigated 
in triplicate. Results are expressed as cell viability percentage ± SD, normalized to the 
control. At the end of the incubation time with CompA and CompB medias, cell 
morphology was evaluated using bright-field microscopy (Leica Microsystem, Milton 
Keynes, UK), at 200x magnification.  
Statistical Analysis 
Results of the CFU and cell viability assays were analyzed with Prism® version 4.03 
(GraphPad Software, San Diego, CA, USA) with 95% confidence intervals (CI) of the 
difference. Linear mixed effect model was used to model the experiment data in order 
to account for repeated measurements.29,30 Shapiro-Wilk W test was used to determine 
the normality of the data. Levene’s test was used to test equal variance between 
treatment groups as it can be used to compare variances between two or more groups. 
One-way Analysis of Variance (ANOVA) was performed to check the difference in 
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means between two or more treatment groups. Lastly, one-tailed and Two-tailed 
Student’s t-tests were used to determine if the means between two groups are different. 
The statistical analyses were performed using JMP® software (SAS, Cary, NC, USA). 
Results 
SEM Analysis 
Figures 1 (a-b) shows the morphologies of biosynthesized (CompA) and cryomilled 
ZnS particles (CompB). Due to particles aggregation during freeze-drying the original 
ZnS aggregates have irregular shape with an average diameter of 2.8 mm with 
standard deviation of 1.5 mm, while the cryomilled ZnS particles have an average 
diameter of 0.8 µm with standard deviation of 0.4 µm, which is a decrease in size in 
excess of three orders of magnitude. Meanwhile, the shape of the particles has been 
altered to more arbitrary shapes with sharp edges. Due to the decrease in size of the 
particles, the surface area to volume ratio has been increased. 
[insert Figure 1.] 
 
XRD Analysis 
Figure 2 shows the XRD profile of the biosynthesized particles. The three major 
diffraction peaks correspond to the (111), (220), (311) planes of crystalline ZnS, 
which match the XRD profile of ZnS sphalerite. The result has shown that ZnS 
sphalerite has a cubic crystal structure with 5.394493 Å in unit cell dimension. 
[insert Figure 2.] 
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Zinc Sulfide Inhibits the Planktonic Growth of S. aureus AH133. ZOI Assay 
Figure 3 shows the ZOI assay result for CompA. Using the ZOI assay, ZnS CompA at 
a level of 50 mg created the zone of inhibition of average of 11.5 ± 0.66 mm whereas 
CompB produced a larger ZOI (18.87 ± 0.90 mm). These results suggest that while 
both compounds inhibit the growth of AH133, CompB is statistically more effective 
(P < 0.005).  
[insert Figure 3.] 
CompA and CompB Inhibit Biofilm Development by S. aureus AH133 
Biofilms were developed and quantified as described in the Materials and Methods 
section. As shown in Figure 4, PEG treatment had no effect on biofilm development 
(control). However, at 15, 25, or 50 mg/disc, CompA and CompB completely 
inhibited the development of AH133 biofilm. At 10 mg/disc of CompA, the biofilm 
was reduced by about 4 logs (Figure 4A). However, treatment of the discs with 10 
mg/disc of CompB reduced the biofilm by about 7 logs (Figure 4B). These results 
suggest that at a minimum concentration of 15 mg/disc, both compounds are very 
effective in inhibiting the development of AH133 biofilm.  
[insert Figure 4.] 
These results were confirmed by the visualization of the biofilm using CLSM. As 
shown in Figure 5 (a-d), on untreated discs and discs treated with PEG, we detected 
well developed mature biofilms (shown in green). In contrast, no biofilms were 
detected on discs treated with 15, 25, or 50 mg/disc of either Comp A or Comp B. On 
discs treated with CompA at a concentration of 10 mg/disc, we detected AH133 
biofilm (Figure 5c). No biofilm was detected on discs treated with 10 mg/disc of 
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Comp B (Figure 5d) confirming that CompB is more effective in inhibiting AH133 
biofilm than CompA.  
[insert Figure 5.] 
CompB interferes with Biofilm Development by Two Methicillin-Resistant S. aureus 
(MRSA) Clinical Isolates 
MRSA strains (both community acquired and hospital acquired) represent major 
bacterial pathogens in wound infection. Routine antibiotic treatment is basically 
ineffective in eliminating MRSA infections. Since our results showed that CompB is 
more effective than Comp A, we tested the efficacy of CompB in inhibiting biofilm 
development by two MRSA isolates (MRSA 121 and MRSA 139) obtained at the 
Texas Tech University Medical Center, Lubbock Texas. As shown in Figure 6A, at 
15mg/disc Comp B reduced MRSA121 biofilm significantly (about 6-fold reduction). 
However, it completely inhibited the biofilm formation at 20 mg/disc (Figure 6A). We 
obtained similar results when we examined CompB with MRSA139 (Figure 6B). 
With MRSA139, 10 mg of CompB reduced the biofilms by about 5-fold while 15 mg 
reduced it by about 8-fold (Figure 6B). These results suggest that CompB is effective 
in inhibiting biofilm development by the two MRSA strains. 
[insert Figure 6.] 
CompA is More Cytotoxic than CompB 
CompA and CompB cell biocompatibility was tested by treating murine macrophages 
RAW264.7 cells with CompA and CompB media for 24 hours. At the end of the 
incubation period, cells were imaged by brightfield microscopy (Figure 7). Brightfield 
images revealed the presence of non-cryomilled particles in medium of cells treated 
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with CompA medium (Figure 7a), while the medium of cells treated with CompB 
(Figure 7b) appeared similar to the control. Moreover, cells incubated with CompA 
failed to reach full confluence (Figure 7c). CellTiter-Blue Cell Viability Assay 
(Figure 8) showed that after 24 hours from the end of cells incubation with CompA 
medium, average cell viability is reduce by 43% in comparison to the controls, 
considered as 100% (CompA medium cell viability = 57 ± 12%), while average of 
viability of cells incubated with CompB medium did not differ from controls (CompB 
medium cell viability = 92 ± 11%). These results were confirmed also 48 hours after 
the end of cells incubation with CompA and CompB media. Average of cell viability 
of cells incubated with CompA is reduced by 42% than controls (58 ± 12%), while 
average of viability of cells incubated with CompB medium did not differ from 
controls (CompB medium cell viability = 99.77 ± 8.04%). Viability of cells treated 
with CompB and CompA are statistically different (p<0.05). Overall, results show 
that there is no difference in cell morphology and cell viability between cells treated 
with CompB and controls, while the viability of cells incubated with CompA is 
reduced by more than 42%, suggesting cell cytotoxicity for CompA and an optimal 
biocompatibility for CompB. 
[insert Figure 7.] 
[insert Figure 8.] 
CompB Inhibits the Growth of S. aureus in Infected Wounds 
We determined the effectiveness of the cream-formulated zinc –nanoparticles 
(CompB) in inhibiting the growth of S. aureus within infected wounds. We 
formulated CompB in polyethylene glycol (PEG) which is water soluble, inert, non-
volatile, and does not hydrolyze or deteriorate. We previously utilized this PEG in 
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formulating another antimicrobial agent.26 In this study, we evaluated the 
effectiveness of CompB in PEG using the murine model of wound infection as 
previously described.26-28 We employed live image analysis to monitor the growth of 
S. aureus within the infected wound.  For this purpose, we utilized a specific S. 
aureus strain, Xen-29, which contains a single copy of the Photorhabdus liminescens 
luxABCDE operon in its chromosome.26,28 As the strain grows within the wound, it 
would emit luminescence, which can be detected by the IVIS Lumina XR system with 
Living Image software.  Once made, the wound was covered with a sterile gauge 
containing 400 mg of either PEG or CompB-PEG.  The materials were evenly 
distributed on the surface of the gauze.  To secure the gauze, we covered it with 
OpSite dressing. We then injected about 1 x 103 CFU of Xen-29 between the gauze 
and the wound. At 1 and 5 days post-infection/treatment, we briefly anesthetized the 
mice and visualized the wounds. As shown in Figure 9 (a-b), in mice treated with 
PEG only, Xen-29 colonized the wound and grew within the infected tissues. 
However, CompB/PEG treatment inhibited the growth of Xen-29 (Figure 9b).  
[insert Figure 9.]        
 
To confirm these results, we determined the number of microorganisms (CFU) 
within the gauze as well as the infected/treated tissue. Mice were infected and treated 
with either PEG or CompB/PEG as described above. At 24 hours post 
infection/treatment, mice were euthanized and the gauzes were separated and 
suspended in PBS. Similarly, infected/treated tissues were excised and suspended in 
PBS. The gauzes and tissues were homogenized and serially diluted (1:10 dilution) to 
determine CFU/gm of tissue or gauze. As shown in Figure 9a, S. aureus grew in both 
the gauze and the infected wound. In contrast, we did not recover any bacterium from 
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either the tissues or gauzes in mice that were treated with CompB/PEG (Fig.10 (A-
B)). These results strongly suggest that the PEG formulated CompB inhibits the 
growth of S. aureus within the infected wound.  
[insert Figure 10.] 
Discussion 
The results have shown the effectiveness of the suggested two-step fabrication 
approach for generating ZnS particles possessing antibacterial properties. It is 
theorized that the enhanced antibacterial properties of the cryomilled ZnS particles 
may originate from a direct deposition mechanism. That is, the effect that direct 
deposition of the particles may have on cell death.31-33 According to Raghupathi et 
al.31, the deposition of particles directly unto the surface of bacteria or their collection 
in the cytoplasm or periplasmic region leads to disruption of cellular activities. It may 
also cause disorder of the membrane thereby contributing towards cell death.31 
CompB, which is the cryomilled sample, showed better antibacterial effectiveness 
than CompA. Therefore, it is understood that the increased antibacterial effectiveness 
of ZnS resulted from the decrease in particle size and increase in surface-to-volume 
ratio that was obtained via cryomilling. As shown in Figure 3, CompB produced 
larger zones of bacterial inhibition than CompA. In addition, CompB was more 
effective than CompA in inhibiting biofilm development by the S. aureus strain 
AH133 (Figures 4 & 5 (a-d)). Furthermore, at 20 mg/disc, CompB inhibited biofilm 
development by the two MRSA strains (Figure 6). Consequently, the outcomes of this 
study direct towards defining the antibacterial mechanism of ZnS as related to the 
direct deposition of particles and the interaction generated between surfaces.31 
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Besides reducing the particle size, cryomilling may enhance the antimicrobial 
properties of CompB by introducing differences in the lattice constant. Sphalerite has 
a cubic crystal structure with lattice constant c of 0.5 nm,34 but mechanical milling 
changes the crystal structure. Past research has shown that milling results in slightly 
higher c values,35 and a lattice relaxation occurs along the axis for zinc oxide.36 The 
increased c value has a significant effect on the amount of H2O2 generated from the 
surface of the particles, which in turn helps the inhibition of bacterial growth.19,37 The 
enhanced effect of the CompB cream against S. aureus biofilms (in comparison with 
CompA) is likely due to the fact that reducing the size of the particles by cryomilling 
enhanced the mixing of the ZnS particles with the PEG base. Furthermore, 
preliminary investigations on CompB powder showed good biocompatibility when 
administered to RAW264.7 macrophages (Figure 8), suggesting that ZnS cryomilled 
powder is not likely to hyper-stimulate macrophages into a foreign-body response.  
Currently used strategies to treat infected wounds include; debridement to 
eliminate bacterial biofilms and remove necrotic tissues, covering the wound with 
wound dressings to protect newly granulating tissues and help maintain moisture 
within the wounds, and the utilization of local and/or systemic antibiotics.  While 
debridement removes bacterial biofilms from the wound surface, it does not eliminate 
bacteria deep within the underlying connective tissues.  Similarly, tissue necrosis 
within the area surrounding the wound bed restricts the blood supply to the wound 
and reduces the effectiveness of systemically administered antibiotics.  Topical 
applications, however, bring the antimicrobial agent in direct and prolonged contact 
with the wound pathogens and their biofilms.  In addition, the antimicrobial agent 
may reach deeper tissues within the wound and eliminate the bacterial within these 
tissues.  Several topical antimicrobial agents have been utilized to treat infected 
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wounds with variable successes.38-40 Using the in vitro wound biofilm model, we 
previously investigated the effectiveness of three commonly used antibiotic ointments 
in preventing the development of S. aureus biofilms. These ointments included: 
gentamicin sulfate, mupirocin, and triple-antibiotic (bacitracin, neomycin, and 
polymixin B). All three ointments reduced biofilms by 0.3-2.0 log10 CFU/disc.8 In 
contrast, formulated CompB completely inhibited the development of S. aureus 
biofilms including those produced by two MRSA clinical isolates (Figs. 4 & 6).  In 
addition, formulated CompB inhibited the growth of S. aureus within infected wounds 
(Figs. 9b & 10) suggesting that CompB is a potential antimicrobial agent to treat 
wound infections.  We plan to examine the effectiveness of the formulated CompB 
against other wound pathogens including; Klebsiella pneumoniae, Staphylococcus 
epidermidis, and Acinetobacter baumannii in our future studies.   
Conclusion 
A novel two-step fabrication approach yielding ZnS particles with antibacterial 
properties for burn wound treatment has been introduced. The ZnS particles were 
biologically, reproducibly and economically synthesized using the anaerobic 
thermophilic metal-reducing bacteria Thermoanaerobacter X513. Smaller sized ZnS 
particles were produced by milling the as-biosynthesized ZnS under a cryogenic 
environment for 56 min. The biosynthesized ZnS and cryomilled ZnS were proven to 
have a significant effect on the growth and biofilm development by Staphylococcus 
aureus. Future experiments will be conducted to examine the effectiveness of the 
cryomilled ZnS particles on the growth and biofilm development by other Gram-
positive and Gram-negative wound pathogens. 
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Figure Captions 
 
Figure 1. SEM images of (a) original freeze-dried ZnS particles (CompA), with 
diameters of around 2.8 mm and standard deviation of 1.5 mm and (b) cryomilled ZnS 
particles (CompB) with average diameter of 0.8 µm and standard deviation of 0.4 µm. 
 
Figure 2. XRD profile of the synthesized ZnS particles with three major peaks 
corresponding to the (111), (220) and (311) crystal planes that match the crystal 
structure of ZnS sphalerite. 
 
Figure 3.  CompA (A) and CompB (B) inhibit the planktonic growth of S. aureus 
strain AH133. The analysis was done using the ZOI assay. 
 
Figure 4.  ZnS ointment inhibits biofilm development by the S. aureus strain AH133.  
Cellulose disks were inoculated with AH133 and covered with pieces of sterile gauze 
containing either CompA-formulated ointment (A) or CompB-formulated ointment 
(B).  Some disks were covered with pieces of sterile gauze containing PEG (ointment 
control) while others were covered with sterile gauze (untreated controls). Values 
represent the means (plus/minus) SE of three independent experiments. 
 
Figure 5. CLSM visualization of the biofilm formed on disks inoculated with AH133 
and treated with either CompA-formulated ointment (A) or CompB-formulated 
ointment (B).  a, untreated control; b, discs treated with PEG (cream base); c, discs 
treated with 10 mg of CompA (A); d, discs treated with 10 mg of CompB (B).  
Experiments were conducted as described in Figure 4.  
 
Figure 6. CompB-formulated cream inhibits biofilm development by the S. aureus 
methicillin resistant (MRSA) clinical isolates 121 (A) and 139 (B).  Experiments were 
conducted as described in Figure 4. Disks were treated with 10, 15, or 20 mg of 
CompB-formulated in PEG. Values represent the means of three independent 
experiments (plus/minus) SE. 
 
Figure 7. Bright field pictures of RAW 264.7 cells the day after incubation with (a) 
CompA medium (uncryomilled ZnS), (b) CompB medium (cryomilled ZnS), and (c) 
Control cells (standard medium). Scale bar=20µm, 200x magnification. 
 
Figure 8. Metabolic activity was measured 24h and 48h after indicated exposure 
conditions. Diagrams display mean ± SD of three independent experiments. 
 
Figure 9. Mice were treated as described in The Murine Model of Wound Infection. 
In vivo live imaging of (a) a representative mouse examined 1 and 5 days after 
treatment with PEG as a control and (b) a representative mouse examined 1 and 5 
days after treatment with CompB/PEG. Images shown are representative of 1 of the 3 
separate replicate experiments. 
 
Figure 10. CompB/PEG inhibits S. aureus biofilm formation within the infected 
wound. Mice were treated as described in Figure 9.  At 24 h post infection/treatment, 
mice were euthanized and the gauze and 15-mm depth samples of wound bed tissue 
were recovered, and homogenized. The homogenates were serially diluted 10-fold and 
10-μl aliquots of each dilution were spotted onto LB agar plates. The numbers of 
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CFU/cm2 of gauze or CFU/g of tissue (A) or CFU/cm2 of gauze (B) as described 
within the text. Values in the graphs represent the means 3 independent experiments ± 
SEM; ****, P = 0.0001. 
 
 
Figure 2. SEM images of (a) original freeze-dried ZnS particles (CompA), with 
diameters of around 2.8 mm and standard deviation of 1.5 mm and (b) cryomilled ZnS 
particles (CompB) with average diameter of 0.8 µm and standard deviation of 0.4 µm.  
 
 
 
Figure 2. XRD profile of the synthesized ZnS particles with three major peaks 
corresponding to the (111), (220) and (311) crystal planes that match the crystal 
structure of ZnS sphalerite. 
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Figure 3.  CompA (A) and CompB (B) inhibit the planktonic growth of S. aureus 
strain AH133. The analysis was done using the ZOI assay. 
 
 
Figure 4.  ZnS ointment inhibits biofilm development by the S. aureus strain AH133.  
Cellulose disks were inoculated with AH133 and covered with pieces of sterile gauze 
containing either CompA-formulated ointment (A) or CompB-formulated ointment 
(B).  Some disks were covered with pieces of sterile gauze containing PEG (ointment 
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control) while others were covered with sterile gauze (untreated controls). Values 
represent the means (plus/minus) SE of three independent experiments. 
-f  
Figure 5. CLSM visualization of the biofilm formed on disks inoculated with AH133 
and treated with either CompA-formulated ointment (A) or CompB ormulated 
ointment (B).  a, untreated control; b, discs treated with PEG (cream base); c, discs 
treated with 10 mg of CompA (A); d, discs treated with 10 mg of CompB (B).  
Experiments were conducted as described in Figure 4.  
 
 
Figure 6. CompB-formulated cream inhibits biofilm development by the S. aureus 
methicillin resistant (MRSA) clinical isolates 121 (A) and 139 (B).  Experiments were 
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conducted as described in Figure 4. Disks were treated with 10, 15, or 20 mg of 
CompB-formulated in PEG.  Values represent the means of three independent 
experiments (plus/minus) SE. 
 
